Royal Bank of Canada
CGEM icon

Royal Bank of Canada’s Cullinan Oncology CGEM Stock Holding History

Royal Bank of Canada’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58K Buy
4,044
+2,492
+161% +$32K ﹤0.01% 5412
2025
Q4 		$16K Buy
1,552
+67
+5% +$604 ﹤0.01% 6165
2025
Q3 		$8K Sell
1,485
-2,994
-67% -$21.9K ﹤0.01% 6555
2025
Q2 		$33K Buy
4,479
+4,410
+6,391% +$35.4K ﹤0.01% 6086
2025
Q1 		$1K Sell
69
-2,250
-97% -$21.6K ﹤0.01% 6637
2024
Q4 		$28K Sell
2,319
-3,216
-58% -$46.2K ﹤0.01% 5963
2024
Q3 		$92K Buy
5,535
+1,847
+50% +$32.8K ﹤0.01% 5399
2024
Q2 		$64K Buy
3,688
+3,108
+536% +$66.2K ﹤0.01% 5526
2024
Q1 		$10K Sell
580
-8,344
-94% -$129K ﹤0.01% 6190
2023
Q4 		$91K Sell
8,924
-832
-9% -$7.37K ﹤0.01% 5671
2023
Q3 		$88K Buy
9,756
+765
+9% +$7.97K ﹤0.01% 5460
2023
Q2 		$97K Buy
8,991
+7,492
+500% +$79.6K ﹤0.01% 5361
2023
Q1 		$15K Sell
1,499
-3,014
-67% -$33.2K ﹤0.01% 6134
2022
Q4 		$47K Buy
4,513
+4,136
+1,097% +$50.2K ﹤0.01% 5914
2022
Q3 		$5K Sell
377
-198
-34% -$2.67K ﹤0.01% 6716
2022
Q2 		$7K Sell
575
-2,172
-79% -$24.6K ﹤0.01% 6508
2022
Q1 		$29K Sell
2,747
-3,781
-58% -$51.1K ﹤0.01% 6395
2021
Q4 		$101K Buy
6,528
+3,718
+132% +$74.2K ﹤0.01% 5923
2021
Q3 		$64K Buy
2,810
+1,903
+210% +$50.9K ﹤0.01% 6006
2021
Q2 		$23K Sell
907
-351
-28% -$10.8K ﹤0.01% 6493
2021
Q1 		$52K Buy
+1,258
New +$51.1K ﹤0.01% 5850

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Royal Bank of Canada's CGEM Position: Q1 2026 in Review

Royal Bank of Canada increased its Cullinan Oncology (CGEM) stake by 161% in Q1 2026, buying an estimated $32K and bringing the position to 4,044 shares worth $58K. The position accounts for ﹤0.01% of the portfolio, ranked #5412.

Royal Bank of Canada first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $101K in Q4 2021. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Royal Bank of Canada held 4,044 shares of Cullinan Oncology worth $58K as of Q1 2026.
  • Royal Bank of Canada bought 2,492 Cullinan Oncology shares in Q1 2026, an estimated $32K.
  • Cullinan Oncology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5412 holding.
  • Royal Bank of Canada first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • Royal Bank of Canada's Cullinan Oncology position peaked at $101K in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.